SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001610717-23-000412
Filing Date
2023-12-19
Accepted
2023-12-19 19:58:44
Documents
1
Period of Report
2023-12-17

Document Format Files

Seq Description Document Type Size
1 form4.html 4  
1 form4.xml 4 5851
  Complete submission text file 0001610717-23-000412.txt   7350
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Issuer) CIK: 0001501989 (see all company filings)

IRS No.: 273521219 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD., SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address
Ogden Christopher (Reporting) CIK: 0001914523 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37587 | Film No.: 231499052